Fundraising Fox

Arrivent

Newtown Square, US · Founded 2021 · 9 known investors

arrivent.com ↗

ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines for difficult-to-treat diseases, starting with cancers. Its pipeline centers on its lead candidate firmonertinib (formerly furmonertinib) and novel oncology therapeutics such as next-generation antibody drug conjugates.

BiotechHealthtechMedical Devices

Founders & leadership

Arrivent was founded in 2021 by Zhengbin (Bing) Yao.

Z(
Zhengbin (Bing) YaoFounder
BR
Brent RiceChief Commercial Officer

Board

JZ
Jason ZhangBoard director
CX
Cong XuBoard director
SL
Stuart LutzkerBoard director

Investors · 9

Catalio Capital Management, LPNew York
Foresite CapitalLarkspur
General CatalystSan Francisco · $30M
HongShan Capital GroupHong Kong · $100K – $50M
LAVHong Kong · $5M – $15M
Lilly Asia VenturesHong Kongvia Hongbo Lu · inferred
OrbiMedNew York · $1M – $75M
NVIDIAreportedSanta Clara
Sofinnova VenturesreportedMenlo Park · $100K – $15M

Reported raises · per SEC filings

Form D private placements

$260M disclosed across 2 rounds · 2021–2022

▶$110MraisedDec 2022 · 17 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Stuart LutzkerDirector
  • James HealyDirector
  • Carl GordonDirector
  • Jason ZhangDirector
  • Zhengbin (Bing) YaoExecutive Officer, Director
  • Bahija JallalDirector
  • Cong XuDirector
Offering amount
$145M
Amount sold
$110M
First sale
Dec 2022
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$150MraisedFeb 2022 · 10 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jason ZhangDirector
  • Cong XuDirector
  • Zhengbin (Bing) YaoExecutive Officer, Director
  • Stuart LutzkerDirector
Offering amount
$150M
Amount sold
$150M
First sale
Jun 2021
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $47.00 - Ticker Reporttickerreport.com · Aug 2026ArriVent BioPharma Reports Second Quarter 2026 Financial Results - BioSpacebiospace.com · Aug 2026ArriVent BioPharma posts $93M H1 2026 net loss | AVBP Quarterly Report (10-Q)stocktitan.net · Aug 2026Venture funding drops in Seattle area as AI boom reshapes startup world – GeekWiregeekwire.com · Jul 2026Seeds | Jumps to World Model Unicorn in One Year! Manifold AI Raises Hundreds of Millions in New Funding | Gasgooautonews.gasgoo.com · Jun 2026Fei-Fei Li's World Labs Raises $1B in Fresh Funding to Advance Development of World Modelstheaiinsider.tech · Feb 2026

Frequently asked questions

What does Arrivent do?
ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines for difficult-to-treat diseases, starting with cancers. Its pipeline centers on its lead candidate firmonertinib (formerly furmonertinib) and novel oncology therapeutics such as next-generation antibody drug conjugates.
Who founded Arrivent?
Arrivent was founded by Zhengbin (Bing) Yao in 2021.
Who are Arrivent's investors?
Arrivent's investors include Catalio Capital Management, LP, Foresite Capital, General Catalyst, HongShan Capital Group, LAV, Lilly Asia Ventures, OrbiMed, NVIDIA and 1 more.
How much funding has Arrivent raised?
Arrivent has disclosed $260M raised across 2 rounds.
Where is Arrivent headquartered?
Arrivent is headquartered in Newtown Square, US.